Treatment of Refractory Diamond-Blackfan Anemia With Eltrombopag

STATUS

Recruiting
End date

Jun 30, 2027
participants needed

25
sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Send

Updated on 19 February 2024

See if I qualify

blood transfusion

corticosteroids

anemia

electrocardiogram

bone marrow biopsy

blood cell count

eltrombopag

cell counts

bone marrow erythroid

Summary

Background

Diamond-Blackfan anemia (DBA) is treated with steroids. But some people cannot take steroids, or steroids don t work. Other patients must get blood transfusions regularly which are time consuming and can have significant side effects. The drug eltrombopag can increase red blood cells. Researchers want to see if it can help people with DBA and, if so, for how long.

Objective

To study the safety and efficacy of eltrombopag in people with DBA who have not responded to steroids or could not take them.

Eligibility

People ages 2 and older with DBA who did not respond to steroids or could not take them, or their disease has returned despite taking them

Design

Participants will be screened with:

Medical and medicine history

Physical exam

MRI: Participants will lie in a machine that takes pictures of the liver.

Blood and urine tests

Bone marrow biopsy: A thin needle will remove a marrow sample from the participant s hip bone.

Electrocardiogram

Participants will take eltrombopag pills once daily for 24 weeks. They will have blood taken every 2 weeks.

Participants will have visits 6 months. At 6 months, they will repeat all the screening tests and also have:

Quality-of-life questionnaire

Neurodevelopmental test (for participants younger than 18 years)

If participants blood cell counts improve, they may keep taking eltrombopag for up to 3 more years. If so, they will have blood taken every 4 weeks. They will visit NIH every 6 months and repeat the above tests.

Participants will be monitored for up to 3 years after they stop taking eltrombopag. They will visit NIH 6 months after treatment ends. If participants blood counts go down after treatment ends, they may restart the drug....

Description

Diamond-Blackfan anemia (DBA) is a heritable bone marrow failure (BMF) syndrome characterized by selective erythroid defects typically presenting within the first year of life as a normochromic, macrocytic anemia with reticulocytopenia. More than half of all DBA cases are associated with either inherited or spontaneous mutations in ribosomal proteins, making DBA a prototypic ribosomopathy . Furthermore, although the primary presentation is isolated anemia, as life expectancy has improved, progressive defects in other lineages have now been identified, consistent with a long-term stem cell defect. Current standard of care for DBA is the use of systemic corticosteroids, the mechanism of which is unclear, although only half show an initial response. Even when a response to steroids is observed, long-term steroid therapy carries significant morbidity, especially in children or in combination with transfusion-associated iron overload, and thus most cannot tolerate high-dose steroids long-term. Responses are rare with second-line immunomodulatory agents. Yet other than allogeneic hematopoietic stem cell transplantation in those patients with healthy matched donors, there are no alternative therapies.

In one model for DBA pathogenesis, the defects lead to an overabundance of the iron-carrying moiety heme in primitive erythroid cells, unbound by protein. Free heme is toxic to cells, likely exacerbated over time by iron overload due to transfusions. Ongoing work with eltrombopag (EPAG) has shown that it is capable of acting as a potent iron chelator, including intracellular iron, with evidence that this effect of EPAG can reverse the impact of excess heme and elevated reactive oxygen species. Furthermore, in a recent trial of EPAG for moderate aplastic anemia or hypoproliferative unilineage cytopenias, we identified a robust response to EPAG in the one DBA patient enrolled in this clinical trial. This response has been durable over more than three years since study entry but requires continuous EPAG to maintain transfusion independence. From these data, we hypothesize that EPAG may be able to improve production of red blood cells in DBA patients via chelation of iron and subsequent reduction in heme synthesis, resulting in decreased toxicity to bone marrow stem cells and developing erythroid cells.

We will conduct a single-arm, pilot trial in patients with steroid-refractory or steroid-intolerant DBA, treating with a fixed dose of EPAG for 6 months to assess safety and efficacy at improving hematological manifestations of DBA. Responders at 6 months will be able to continue EPAG on the extension part of this protocol for an additional 3 years. We will examine the hematologic, molecular, cytogenetic and clonal responses to EPAG in responders and non-responders alike. Translational studies will examine the mechanism of activity of EPAG in DBA through its effects on iron metabolism, erythroid differentiation, apoptosis, global transcriptome and TPO signaling pathways in patient s hematopoietic stem and progenitor cells (HSPCs).

Details

Condition	Diamond-Blackfan anemia
Age	2-100 years
Treatment	Eltrombopag
Clinical Study Identifier	NCT04269889
Sponsor	National Heart, Lung, and Blood Institute (NHLBI)
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	In order to be participate in this study, individuals must meet all of the
	following
	criteria
	Diamond-Blackfan anemia defined as anemia presenting on or before the third year of life with reticulocytopenia and greatly reduced or absent bone marrow erythroid precursors, supported by, but not requiring either
	familial history
	gene mutation testing demonstrating a known disease-causing mutation or a mutation of disease-associated gene in combination with clinical characteristics of DBA
	Clinically-significant anemia as defined as either
	hemoglobin less than 9.0 g/dL
	red cell transfusion of at least 2 units PRBC for adults or 30 cc/kg for children (whichever is less) in the eight weeks prior to study enrollment
	Relapsed and/or steroid-refractory or intolerant of systemic corticosteroids
	Age greater than or equal to 2 years
	Weight greater than or equal to 12 kilograms
	Residence within the United States of America or territories, or able to reside within the US or its territories while on drug during trial participation
Exclusion Criteria
	Individuals meeting any of the following criteria will not be eligible for
	participation in this study. However, having met exclusion criteria in the
	past does not preclude study participation if the criteria are no longer met
	unless otherwise specified (i.e. patients with modifiable factors such as
	laboratory abnormalities or acute health problems may be re-screened). For
	laboratory assessments, this requires no less than two weeks from the previous
	exclusionary finding. The intervals for health problems that must elapse prior
	to re-screening are specified below
	Platelet count > 400,000 / microliter
	Stage 4 or greater kidney disease as defined by creatinine > 2.5 mg/ dL or GFR < 30 mL/min/1.73 m(2)
	\--For pediatric patients 17-years-old or younger, GFR shall be used. This can
	be estimated using the bedside Schwartz equation, the Counahan-Barratt method
	or a similar methodology. Direct measurement including, but not limited to
	-hour urine creatinine clearance or radiographic methods is recommended for
	patients with stage 3 disease (GFR less than or equal to 45 mL/min/1.73 m(2))
	Direct bilirubin > 2.0 mg/ dL, including congenital abnormalities in the bilirubin level
	SGOT (AST) or SGPT (ALT) > 5 times the upper limit of normal
	Treatment with androgens (danazol or oxymetholone) or corticosteroids less than 4 weeks prior to initiating eltrombopag
	\--Physiologic steroid replacement for adrenal insufficiency or other similar
	conditions is not exclusive of trial participation
	Treatment with any medications that may interfere with the metabolism of eltrombopag (e.g., CYP1A2 and CYP2C8 modulators) or whose own altered metabolism by eltrombopag cannot be adjusted for
	Hypersensitivity to eltrombopag or its components
	Moribund status or concurrent hepatic, renal, cardiac, neurologic, pulmonary, infectious, or metabolic disease of such severity that it would preclude the patient s ability to tolerate protocol therapy, or that death within 7-10 days is likely
	Life expectancy of less than 3 months for any cause
	Subjects with known liver cirrhosis in severity that would preclude tolerability of eltrombopag as evidenced by albumin < 3.5g/dL
	History or current diagnosis of cardiac disease indicating significant risk of safety for patients participating in the study such as uncontrolled or significant cardiac disease, including any of the following
	Recent myocardial infarction (within last 6 months)
	Uncontrolled congestive heart failure
	Unstable angina (within last 6 months)
	Clinically significant (symptomatic) cardiac arrhythmias (e.g., sustained ventricular tachycardia, and clinically significant second or third-degree AV block without a pacemaker.)
	Long QT syndrome, family history of idiopathic sudden death, congenital long QT syndrome or additional risk factors for cardiac repolarization abnormality, as determined by the investigator
	Impaired cardiac function such as corrected QTc>450msec using Fridericia correction on the screening EKG, other clinically significant cardio-vascular disease (e.g. uncontrolled hypertension, history of labile hypertension), history of known structural abnormalities (e.g. cardiomyopathy)
	Known active or uncontrolled infections not adequately responding to appropriate therapy
	\--HIV infection is not exclusive of trial participation if the infection is
	effectively controlled with medications not known to interfere with
	eltrombopag metabolism or be metabolized by pathways known to be altered by
	eltrombopag. HIV RNA viral load must be undetectable at the time of
	enrollment, and CD4 cell count must be greater than or equal to
	microliter. Patients must remain on antiretroviral therapy throughout
	study participation and must be periodically monitored for suppression of
	viral load and CD4 cell count. If drug-drug interactions between
	antiretroviral medications and eltrombopag are suspected, these must be
	addressed by a qualified clinical pharmacist or pharmacologist, and any
	changes to antiretroviral therapy need to be approved in consultation with an
	Infectious Disease and/or HIV specialist prior to enrollment
	Active malignancy or likelihood of recurrence of malignancies within 12 months
	Evidence for MDS or AML as defined by WHO criteria
	Patients who have received chemotherapeutic treatment or other specific antineoplastic drugs or radiation therapy within 6 months of study entry
	Female subjects who are nursing or pregnant (positive serum or urine beta-human chorionic gonadotrophin (b-hCG) pregnancy test) at screening or pre-dose on Day 1
	Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 30 days after the last dose of eltrompobag. Highly effective contraception methods include
	Total abstinence (when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
	Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment
	Male sterilization (at least 6 months prior to screening). For female patients on the study the vasectomized male partner should be the sole partner for that patient
	Use of oral, injected or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS), or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception
	In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment
	Women are considered post-menopausal and not of child bearing potential if they have had over 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile age appropriate (e.g. generally 40-59 years), history of vasomotor symptoms (e.g. hot flushes) in the absence of other medical justification or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment should she be considered not of child bearing potential
	Sexually active males unless they use a condom during intercourse while taking the study treatment and for 30 days after stopping study treatment and should not father a child in this period. A condom is required to be used also by vasectomized men as well as during intercourse with a male partner in order to prevent delivery of the drug via seminal fluid
	History of thromboembolic events other than catheter-related thromboses
	Active alcohol/drug abuse
	Unable to understand the investigational nature of the study or give informed consent and does not have a legally authorized representative or surrogate that can provide informed consent
	Unable to take investigational drug
	Concurrent participation in an investigational study within 30 days prior to enrollment or within 5-half-lives of the investigational product, whichever is longer. Note: parallel enrollment in a disease registry is permitted

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

bone marrow erythroid

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study Definition

Wikipedia

Treatment of Refractory Diamond-Blackfan Anemia With Eltrombopag